SG11201407981RA - Compositions comprising an anti-pdgf aptamer and a vegf antagonist - Google Patents
Compositions comprising an anti-pdgf aptamer and a vegf antagonistInfo
- Publication number
- SG11201407981RA SG11201407981RA SG11201407981RA SG11201407981RA SG11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- inventor
- compositions
- rule
- executor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181495 A2 (51) International Patent Classification: A61K39/395 (2006.01) A61K31/711 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043536 31 May 2013 (31.05.2013) English English (30) Priority Data: 61/654,672 61/778,208 1 June 2012 (01.06.2012) US 12 March 2013 (12.03.2013) US (71) Applicants: OPHTHOTECH CORPORATION [US/US]; 5 Vaughn Drive, Suite 106, Princeton, New Jer sey 08540 (US). EVERETT, Zoe (executor for the de ceased inventor) [US/US]; 25 Timber Lane, Randolph, New Jersey 07856 (US). GELTMAN, Marcia (executor for the deceased inventor) [US/US]; 20 Valley Road, Suite 300, Mount Arlington, New Jersey 07856 (US). GIELOW, Richard (executor for the deceased inventor) [US/US]; 2277 Oyster Bay Lane, #2104E, Gulf Shores, Alabama 36542 (US). (72) Inventor: EVERETT, Richard (deceased). (72) Inventor: CHANG, Byeong Seon; 14735 Sutton Street, Sherman Oaks, California 91403 (US). (74) Agents: LANGER, Matthew E. et al.; Cooley LLP, 1299 Pennsylvania Ave, Suite 700, Washington, District of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17 : — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST FIG 77 < 1 o\ T-H 00 T-H rn i-H (57) Abstract: The present invention directed is to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In cer- O tain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease. N 10-2.5 10 0 0 Cone fnM)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261654672P | 2012-06-01 | 2012-06-01 | |
US201361778208P | 2013-03-12 | 2013-03-12 | |
PCT/US2013/043536 WO2013181495A2 (en) | 2012-06-01 | 2013-05-31 | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407981RA true SG11201407981RA (en) | 2015-01-29 |
Family
ID=49674074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407981RA SG11201407981RA (en) | 2012-06-01 | 2013-05-31 | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150182623A1 (en) |
EP (1) | EP2854844A4 (en) |
JP (1) | JP2015519373A (en) |
KR (1) | KR20150033620A (en) |
CN (1) | CN104619335A (en) |
AR (1) | AR091237A1 (en) |
AU (1) | AU2013267310A1 (en) |
CA (1) | CA2874412A1 (en) |
CL (1) | CL2014003233A1 (en) |
CO (1) | CO7240393A2 (en) |
EA (1) | EA201492289A1 (en) |
HK (1) | HK1207983A1 (en) |
IL (1) | IL235797A0 (en) |
MX (1) | MX2014014445A (en) |
PH (1) | PH12014502577A1 (en) |
SG (1) | SG11201407981RA (en) |
TW (1) | TW201400122A (en) |
WO (1) | WO2013181495A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201708882TA (en) | 2013-07-12 | 2017-12-28 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CA2958017A1 (en) * | 2014-08-11 | 2016-02-18 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
CN105435221B (en) * | 2014-09-22 | 2021-09-28 | 正大天晴药业集团股份有限公司 | Pharmaceutical composition of humanized antibody for vascular endothelial growth factor |
US10894083B2 (en) | 2015-01-28 | 2021-01-19 | Pfizer Inc. | Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation |
CN105806830B (en) * | 2015-12-10 | 2019-01-29 | 北京联众泰克科技有限公司 | A kind of stable HRP enzyme-catalyzed chemical luminescence substrate liquid, preparation method and application |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
AU2017213103B2 (en) * | 2016-01-26 | 2022-08-11 | Formycon Ag | Liquid formulation of a VEGF antagonist |
BR112018014467A2 (en) * | 2016-02-04 | 2018-12-11 | Ni Jinsong | drug-antibody synergism technology for disease treatment |
CN108718522A (en) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | IL-6 antagonist formulations and application thereof |
WO2018094316A1 (en) * | 2016-11-21 | 2018-05-24 | Just Biotherapeutics, Inc. | Aflibercept formulations and uses thereof |
KR101861163B1 (en) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | Ophthalmic pharmaceutical composition |
US20210170029A1 (en) * | 2017-11-20 | 2021-06-10 | Just-Evotec Biologies, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
MX2020011848A (en) | 2018-05-10 | 2021-03-29 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations. |
WO2020087003A1 (en) * | 2018-10-26 | 2020-04-30 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021125852A1 (en) * | 2019-12-17 | 2021-06-24 | 주식회사 프로젠 | Novel injectable formulation |
AU2021232369A1 (en) * | 2020-03-04 | 2022-09-22 | Shanghai Henlius Biotech, Inc. | Pharmaceutical formulation comprising bevacizumab |
US20230270670A1 (en) * | 2020-07-24 | 2023-08-31 | Pangen Biotech Inc. | Ophthalmic liquid composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759472B2 (en) * | 2003-08-27 | 2010-07-20 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
HUE053612T2 (en) * | 2006-06-16 | 2021-07-28 | Regeneron Pharma | Vegf antagonist formulations suitable for intravitreal administration |
EP3028707A1 (en) * | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
BR112013004581A2 (en) * | 2010-08-26 | 2017-06-27 | Abbvie Inc | dual variable domain immunoglobulins and their uses |
-
2013
- 2013-05-31 JP JP2015515222A patent/JP2015519373A/en active Pending
- 2013-05-31 TW TW102119528A patent/TW201400122A/en unknown
- 2013-05-31 AR ARP130101931 patent/AR091237A1/en unknown
- 2013-05-31 CA CA2874412A patent/CA2874412A1/en not_active Abandoned
- 2013-05-31 KR KR20147036638A patent/KR20150033620A/en not_active Application Discontinuation
- 2013-05-31 EP EP13796692.5A patent/EP2854844A4/en not_active Withdrawn
- 2013-05-31 MX MX2014014445A patent/MX2014014445A/en unknown
- 2013-05-31 AU AU2013267310A patent/AU2013267310A1/en not_active Abandoned
- 2013-05-31 WO PCT/US2013/043536 patent/WO2013181495A2/en active Application Filing
- 2013-05-31 SG SG11201407981RA patent/SG11201407981RA/en unknown
- 2013-05-31 CN CN201380035401.4A patent/CN104619335A/en active Pending
- 2013-05-31 EA EA201492289A patent/EA201492289A1/en unknown
-
2014
- 2014-11-19 PH PH12014502577A patent/PH12014502577A1/en unknown
- 2014-11-20 IL IL235797A patent/IL235797A0/en unknown
- 2014-11-26 US US14/554,894 patent/US20150182623A1/en not_active Abandoned
- 2014-11-27 CL CL2014003233A patent/CL2014003233A1/en unknown
- 2014-12-26 CO CO14284190A patent/CO7240393A2/en unknown
-
2015
- 2015-09-06 HK HK15108671.2A patent/HK1207983A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2014014445A (en) | 2015-08-14 |
PH12014502577A1 (en) | 2015-01-21 |
JP2015519373A (en) | 2015-07-09 |
EA201492289A1 (en) | 2015-05-29 |
US20150182623A1 (en) | 2015-07-02 |
AU2013267310A1 (en) | 2014-12-11 |
EP2854844A2 (en) | 2015-04-08 |
WO2013181495A2 (en) | 2013-12-05 |
EP2854844A4 (en) | 2016-11-23 |
CL2014003233A1 (en) | 2015-06-19 |
WO2013181495A3 (en) | 2014-02-13 |
CN104619335A (en) | 2015-05-13 |
KR20150033620A (en) | 2015-04-01 |
IL235797A0 (en) | 2015-01-29 |
AR091237A1 (en) | 2015-01-21 |
HK1207983A1 (en) | 2016-02-19 |
CA2874412A1 (en) | 2013-12-05 |
TW201400122A (en) | 2014-01-01 |
CO7240393A2 (en) | 2015-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
SG11201811490XA (en) | Cd3 binding antibodies | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201804162WA (en) | Compositions comprising bacterial strains | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201407268SA (en) | Nuclear transport modulators and uses thereof | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201407483YA (en) | Compositions and methods for modulating smn gene family expression | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201407789RA (en) | Humanized non-human animals with restricted immunoglobulin heavy chain loci | |
SG11201407028WA (en) | St2l antagonists and methods of use | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201408261UA (en) | Syringe | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression |